Clinical

Focusing on patients with latent tuberculosis (TB) infection who are at high risk of developing active TB may be key to eliminating the disease in the United States; however, a study found that physicians are not systematically identifying risk levels for patients with latent TB.

Patients with multiple sclerosis (MS) who also have food allergies have more relapses than patients with no known food allergy, according to a new study published in the Journal of Neurology, Neurosurgery & Psychiatry.

There have been incredible responses to treatments for chronic lymphocytic leukemia (CLL), but there remains a tremendous unmet need for patients, said Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society.

Ibrutinib-containing regimens have similar overall survival rates but significantly higher progression-free survival (PFS) rates at 2 years compared with bendamustine plus rituximab.

Patients who visit the emergency department for pain are often asked to categorize their pain level using a visual scale of numbered faces. However, a recent study suggests the efficacy of a more empirical approach, through the use of an electroencephalography (EEG)-based test, that would be beneficial for both patients and physicians.

Multiple sclerosis (MS) is a progressive neurological disease that requires timely management, and a panel of neurologists has developed an internationally applicable standard of care for timely management in patients with MS.

The FDA has issued a safety warning that patients who stopped taking Gilenya experienced worsening of multiple sclerosis, compared with before treatment started or during treatment, in rare cases.

In patients who relapse after allogeneic hematopoietic stem-cell transplantation, the therapeutic benefits that transplantation provide is diminished through mechanisms that remain unclear. A new study analyzed the genetic and epigenetic alterations of leukemic cells to determine any common features of relapse after transplantation

FDA has recently approved 2 new treatments for patients age 75 and older who are newly diagnosed with AML and have other chronic health conditions or diseases that may mean they cannot use intensive chemotherapy.